Curemark has built a broad product pipeline that addresses an array of disorders.
The company’s lead asset, CM-AT, is an orally-delivered treatment for Autism Spectrum Disorder (ASD). CM-AT is designed to treat the maladaptive behaviors of irritability, agitation, hyperactivity, non-compliance and inappropriate speech in children with Autism as young as age 3. The Phase III, placebo-controlled, randomized clinical trial has been completed and the program continues to advance towards commercialization.
